Skip to content

Salarius

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
  • Our Programs
    • Epigenetics
    • LSD1
    • Pipeline
    • Publications
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
      • Corporate Governance
      • Committee Composition
    • Press Releases
    • In The News
    • Financial Reports
      • Annual Reports
      • Quarterly & Other Reports
      • Tax Documents
    • SEC Filings
    • Events & Presentations
    • Investor Resources
      • Investor FAQs
      • Information Request
      • E-mail Alerts
      • Contact IR
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
    • Analyst Coverage
  • Contact Us
Search

Our Programs

  • Epigenetics
  • LSD1
  • Pipeline
  • Publications
  • Clinical Trials

Publications

LSD1’s Role in Cancer

Nature Immunology

Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis

Cell

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

ACS chemical biology

Lysine-specific histone demethylase 1 inhibitors control breast cancer proliferation in ERα-dependent and-independent manners.

Cancer cell

Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase

More

SP-2577 and Analogs

American Association for Cancer Research

The reversible LSD1 inhibitor SP-2509 promotes anti-tumor immunity in small cell carcinoma of the ovary-hypercalcemic type (SCCOHT)

Molecular Oncology

Preclinical studies reveal that LSD 1 inhibition results in tumor growth arrest in lung adenocarcinoma independently of driver mutations

Oncogene

Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade

Molecular Cancer Research

Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1

More

Salarius

  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Programs
    • Epigenetics
    • LSD1
    • Pipeline
    • Publications
    • Clinical Trials
  • News & Events
    • Press Releases
    • Events
    • In the News
  • Investors
    • Overview
    • Corporate Governance
    • Press Releases
    • In The News
    • Financial Reports
    • SEC Filings
    • Events & Presentations
    • Investor Resources
    • Stock Information
    • Analyst Coverage
  • Contact Us
  • Like Us on Facebook
  • Follow Us on Twitter
  • Connect on LinkedIn
© 2021 Salarius Pharmaceuticals, Inc. All Rights Reserved. Privacy and Terms of Use